The terminal elimination half-life of 18.2 days in patients with gMG confers a convenient interval between doses and provides some allowance for day-to-day fluctuations in C5 concentrations [e.g., as a result of complement-activating events, such as infection, surgery (including thymectomy), or pregnancy, which may increase C5 concentrations], and for slight variation in dosing schedules (± 2 days), without risk of incomplete terminal complement inhibition (22, 23). The gene discussed is C5; the disease is infection.